Episode Synopsis "Efficacy and Safety Trends with Continuous Longterm Use of Crisaborole Ointment 2% in Patients with Mild-to-Moderate Atopic Dermatitis"

The poster was presented by Dr. Lebwohl and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.  This audio commentary is provided by Dr. Steve Feldman.

Listen "Efficacy and Safety Trends with Continuous Longterm Use of Crisaborole Ointment 2% in Patients with Mild-to-Moderate Atopic Dermatitis"

More episodes of the podcast Research Developments in Atopic Dermatitis

• Introduction and Overview
• Efficacy and Safety Trends with Continuous Longterm Use of Crisaborole Ointment 2% in Patients with Mild-to-Moderate Atopic Dermatitis
• Safety, Efficacy and Pharmacokinetics of Crisaborole Ointment 2% in Infants Age Three to Less Than 24 Months with Mild-to-Moderate Atopic Dermatitis
• Association Between an Itch-Free State in Atopic Dermatitis Treated with Ruxolitinib Cream and Systemic Inflammatory Mediators
• Dupilumab Treatment for up to Three Years Demonstrates Sustained Efficacy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Liberty AD Adult Open Label Extension
• Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis
• Peak Pruritus Numeric Rating Scale, the PPNRS, Response with Abrocitinib in Patients with Moderate to Severe Atopic Dermatitis: Results from a Randomized Phase 3 Clinical Trial
• Dupilumab Treatment Results in Rapid Improvement in Itch in Adults and Adolescent Patients with Moderate to Severe Atopic Dermatitis
• Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: An Analysis of a Retrospective Claims Database
• Other posters of interest